Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy

被引：36

作者：

Lai-Kwon, Julia ^{[1
]}

Heynemann, Sarah ^{[1
]}

Flore, Jacinthe ^{[2
]}

Dhillon, Haryana ^{[3
,4
]}

Duffy, Mary ^{[5
]}

Burke, John

Briggs, Lisa

Leigh, Lillian

Mileshkin, Linda ^{[1
,5
,6
]}

Solomon, Benjamin ^{[1
,5
,6
]}

Ball, David ^{[5
,7
]}

Kokanovic, Renata ^{[2
]}

Jefford, Michael ^{[1
,6
,8
]}

机构：

[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia

[2] RMIT Univ, Social & Global Studies Ctr, Melbourne, Vic, Australia

[3] Univ Sydney, Sch Psychol, Ctr Med Psychol & Evidence Based Decis Making, Fac Sci, Sydney, NSW, Australia

[4] Univ Sydney, Sch Psychol, Psychooncol Cooperat Res Grp, Fac Sci, Sydney, NSW, Australia

[5] Peter MacCallum Canc Ctr, Lung Serv, Melbourne, Vic, Australia

[6] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia

[7] Peter MacCallum Canc Ctr, Dept Radiat Oncol, Melbourne, Vic, Australia

[8] Peter MacCallum Canc Ctr, Dept Hlth Serv Res, Melbourne, Vic, Australia

来源：

JOURNAL OF CANCER SURVIVORSHIP | 2021年 / 15卷 / 03期

关键词：

Lung cancer; Survivorship; Targeted therapy;

D O I：

10.1007/s11764-021-01024-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose Immunotherapy (IT) and targeted therapy (TT) have improved survival for some patients with metastatic non-small cell lung cancer (NSCLC). Their lived experience is under-studied. We conducted a single centre, qualitative study to understand concerns and unmet needs amongst this novel survivor population. Methods Eligible participants had metastatic NSCLC, aged >18, English-speaking and >6 months post initiation of IT/TT without progressive disease. Semi-structured interviews focused on physical, psychological, social and functional impacts of diagnosis, therapy and prognosis. Interviews were recorded and transcribed. Data were analysed via qualitative thematic analysis. Results Between May and December 2019, 20 participants were interviewed: median age 62 (range 34-83), 13 (65%) female; median time since diagnosis of metastatic NSCLC 27 months (range 10-108). Twelve out of 20 (60%) participants had a targetable mutation (EGFR/ALK/BRAF); 6 were receiving IT, 11 TT, 2 IT + chemotherapy and 1 IT + TT. Four main themes were identified: living long-term on IT and TT (chronic toxicities), psychological concerns (living with uncertainty, fear of cancer progression, scan-related anxiety), support with practical issues (finances, employment amidst prognostic uncertainty, challenges with trial participation) and wanting information pertinent to NSCLC subtype. Conclusions Longer-term survivors of metastatic NSCLC experience significant physical, psychological and functional concerns and unmet needs. Results will inform a broader cross-sectional survey and resources to address the needs of this growing survivor group. Implications for Cancer Survivors A 'one-size-fits-all' approach to NSCLC survivorship is no longer appropriate. Survivors of metastatic NSCLC treated with novel therapies may benefit from specific information regarding long-term toxicities and psychological supports.

引用

页码：392 / 397

页数：6

共 10 条

[1] KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50% [J].

Brahmer, J. R. ;

Rodriguez-Abreu, D. ;

Robinson, A. G. ;

Hui, R. ;

Csoszi, T. ;

Fulop, A. ;

Gottfried, M. ;

Peled, N. ;

Tafreshi, A. ;

Cuffe, S. ;

O'Brien, M. ;

Rao, S. ;

Hotta, K. ;

Leal, T. A. ;

Riess, J. W. ;

Jensen, E. ;

Zhao, B. ;

Pietanza, M. C. ;

Reck, M. .

ANNALS OF ONCOLOGY, 2020, 31 :S1181-S1182

[2] The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification [J].

Detterbeck, Frank C. ;

Nicholson, Andrew G. ;

Franklin, Wilbur A. ;

Marom, Edith M. ;

Travis, William D. ;

Girard, Nicolas ;

Arenberg, Douglas A. ;

Bolejack, Vanessa ;

Donington, Jessica S. ;

Mazzone, Peter J. ;

Tanoue, Lynn T. ;

Rusch, Valerie W. ;

Crowley, John ;

Asamura, Hisao ;

Rami-Porta, Ramon .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (05) :639-650

[3] The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors [J].

Lai-Kwon, Julia ;

Khoo, Chloe ;

Lo, Serigne ;

Milne, Donna ;

Mohamed, Mustafa ;

Raleigh, Jeanette ;

Smith, Kortnye ;

Lisy, Karolina ;

Sandhu, Shahneen ;

Jefford, Michael .

JOURNAL OF CANCER SURVIVORSHIP, 2019, 13 (04) :503-511

[4] Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy [J].

Levy, David ;

Dhillon, Haryana M. ;

Lomax, Anna ;

Marthick, Michael ;

McNeil, Catriona ;

Kao, Steven ;

Lacey, Judith .

SUPPORTIVE CARE IN CANCER, 2019, 27 (05) :1845-1852

[5]

Mamoor M, 2020, J IMMUNOTHER CANCER, V8

[6] Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice [J].

McLouth, Laurie E. Steffen ;

Lycan, Thomas W., Jr. ;

Levine, Beverly J. ;

Gabbard, Jennifer ;

Ruiz, Jimmy ;

Farris, Michael ;

Grant, Stefan C. ;

Pajewski, Nicholas M. ;

Weaver, Kathryn E. ;

Petty, W. Jeffrey .

CLINICAL LUNG CANCER, 2020, 21 (03) :255-+

[7] Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study [J].

Mok, T. ;

Camidge, D. R. ;

Gadgeel, S. M. ;

Rosell, R. ;

Dziadziuszko, R. ;

Kim, D-W ;

Perol, M. ;

Ou, S-H, I ;

Ahn, J. S. ;

Shaw, A. T. ;

Bordogna, W. ;

Smoljanovic, V ;

Hilton, M. ;

Ruf, T. ;

Noe, J. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2020, 31 (08) :1056-1064

[8] The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life [J].

Park, Rebekah ;

Shaw, James W. ;

Korn, Alix ;

McAuliffe, Jacob .

JOURNAL OF CANCER SURVIVORSHIP, 2020, 14 (03) :363-376

[9] Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC [J].

Ramalingam, S. S. ;

Vansteenkiste, J. ;

Planchard, D. ;

Cho, B. C. ;

Gray, J. E. ;

Ohe, Y. ;

Zhou, C. ;

Reungwetwattana, T. ;

Cheng, Y. ;

Chewaskulyong, B. ;

Shah, R. ;

Cobo, M. ;

Lee, K. H. ;

Cheema, P. ;

Tiseo, M. ;

John, T. ;

Lin, M-C ;

Imamura, F. ;

Kurata, T. ;

Todd, A. ;

Hodge, R. ;

Saggese, M. ;

Rukazenkov, Y. ;

Soria, J-C ;

Boyer, Michael ;

Lee, Chee ;

Hughes, Brett ;

O'Byrne, Kenneth ;

Briggs, Peter ;

Milward, Michael ;

John, Thomas ;

Demedts, Ingel ;

Vansteenkiste, Johan ;

Bustin, Frederique ;

Barrios, Carlos Henrique ;

Timcheva, Constanta ;

Butts, Charles ;

Goss, Glenwood ;

Juergens, Rosalyn ;

Leighl, Natasha ;

Cheng, Susanna ;

Burkes, Ronald ;

Zhou, Caicun ;

Zhang, Helong ;

Shu, Yongqian ;

Cheng, Ying ;

Zhou, Qing ;

Li, Wei ;

Feng, Guosheng ;

He, Yong .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01) :41-50

[10] Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study [J].

Rogiers, A. ;

Leys, C. ;

De Cremer, J. ;

Awada, G. ;

Schembri, A. ;

Theuns, P. ;

De Ridder, M. ;

Neyns, B. .

SUPPORTIVE CARE IN CANCER, 2020, 28 (07) :3267-3278

← 1 →